Menlo Therapeutics Revenue and Competitors

Claim your profile



Total Funding


Estimated Revenue & Valuation

  • Menlo Therapeutics's estimated annual revenue is currently $10.6M per year.(i)
  • Menlo Therapeutics's estimated revenue per employee is $3,546,667
  • Menlo Therapeutics's total funding is $159.8M.

Employee Data

  • Menlo Therapeutics has 3 Employees.(i)
  • Menlo Therapeutics grew their employee count by 0% last year.

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Menlo Therapeutics News

2022-04-13 - VYNE Therapeutics (NASDAQ:VYNE) Upgraded by Zacks ...

The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo...

2022-04-06 - Corcept Therapeutics Announces Appointment of Three Senior Leaders

MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged...

2022-03-22 - Bay Area's first stock debut in nearly 2 months, by AN2 ...

The Menlo Park biotech raised $69 million in an offering that priced in the middle of its target range but sold 900,000 more shares than...

2019-09-12 - Janus Henderson Group PLC Lowers Holdings in Menlo Therapeutics Inc (NASDAQ:MNLO)

Janus Henderson Group PLC lowered its position in Menlo Therapeutics Inc (NASDAQ:MNLO) by 0.5% during the 2nd quarter, according to ...

2019-09-12 - JPMorgan Chase & Co. Lowers Stock Holdings in Menlo Therapeutics Inc (NASDAQ:MNLO)

JPMorgan Chase & Co. reduced its position in shares of Menlo Therapeutics Inc (NASDAQ:MNLO) by 4.1% in the 2nd quarter, according to the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding